Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a confirmed diagnosis of Multiple Sclerosis (MS).
- People who have been prescribed the medication BRIUMVI® (ublituximab-xiiy) but have not yet received any infusion of it before the study begins.
Who may not be able to join:
- People who have received a live or live-attenuated vaccine (such as vaccines for chickenpox or measles) within the 4 weeks before their first BRIUMVI® infusion, or any other type of vaccine within 2 weeks before their first BRIUMVI® infusion.
- People who currently have an active infection (for example, an active Hepatitis B infection).
- People who are already taking part in another MS clinical trial that involves a treatment or intervention, or who plan to use other MS medications alongside the study treatment during the trial period.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-575-8489
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Annualized Relapse Rate (ARR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.